DREAMM-2 Put GSK’s BCMA Drug In Pole Position In Multiple Myeloma

 
• By Sten Stovall

The DREAMM-2 trial of the antibody-drug conjugate belantamab mafodotin in relapsed/refractory multiple myeloma patients has hit its primary endpoint, giving GSK a chance to file for approval before its BCMA rivals.

Start_Line
GSK DREAMM-ing of a quick start

More from Clinical Trials

More from R&D